Crescent Biopharma, Inc. (CBIO) shareholders
CBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 10/30
$14.15−0.22 (-1.53%)
Close on Nov 13, 2026Market cap $525.59MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
79.7%
30M of 37M shares
Institutional holders
82
31 new, 12 sold out
Net institutional buying
4M
In Q2 2026
Insider trades, 12 months
2 buys · 16 sales
Net bought $29.10M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Invus Public Equities Advisors, LLC Joint filing with Invus Public Equities, L.P. (13.30%), Artal International S.C.A (13.30%) and 5 more | 8,589,064 | 13.30% | 13G (passive) amendment | Dec 31, 2023 |
| Peter Harwin Joint filing with Fairmount Funds Management LLC (16.50%), Fairmount Healthcare Fund II L.P. (16.50%) and 1 more | 6,602,408 | 16.52% | 13D (active) amendment | Jul 16, 2026 |
| Peter Evan Harwin Joint filing with Fairmount Funds Management LLC (18.53%), Fairmount Healthcare Fund II L.P. (18.53%) and 1 more | 5,643,482 | 18.53% | 13D (active) amendment | Dec 4, 2025 |
| Abigail P. Johnson Joint filing with FMR LLC (15.00%) | 4,133,514 | 15.00% | 13G (passive) amendment | Dec 31, 2025 |
| Tomas Kiselak Joint filing with Fairmount Funds Management LLC (19.99%), Fairmount Healthcare Fund II L.P. (19.99%) and 1 more | 3,124,220 | 19.99% | 13D (active) | Jun 13, 2025 |
| Bong Y. Koh Joint filing with Venrock Healthcare Capital Partners III, L.P. (9.50%), VHCP Co-Investment Holdings III, LLC (9.50%) and 4 more | 2,666,064 | 9.50% | 13G (passive) amendment | Dec 31, 2025 |
| BlackRock, Inc. | 2,075,291 | 5.60% | 13G (passive) | Sep 30, 2026 |
| ForGrowth III PA B.V. Joint filing with Forbion Growth Opportunities Fund III Cooperatief U.A. (6.10%), Forbion Growth III Management B.V. (6.10%) | 1,677,852 | 6.10% | 13G (passive) | Dec 8, 2025 |
| Dames GP LLC Joint filing with Balyasny Asset Management L.P. (6.03%), Bam Gp LLC (6.03%) and 2 more | 1,662,917 | 6.03% | 13G (passive) amendment | Jun 30, 2026 |
| Bam Gp LLC Joint filing with Balyasny Asset Management L.P. (5.48%), Balyasny Asset Management Holdings LP (5.48%) and 2 more | 1,510,033 | 5.48% | 13G (passive) | Mar 31, 2026 |
| Ryan Wilder Joint filing with Vestal Point Capital, LP (5.40%) | 1,500,000 | 5.40% | 13G (passive) | Dec 31, 2025 |
| 1Globe Capital LLC Joint filing with Jiaqiang Li (10.30%) | 1,425,432 | 10.30% | 13G (passive) amendment | Oct 7, 2025 |
| FMR LLC Joint filing with Abigail P. Johnson (10.20%) | 1,414,190 | 10.20% | 13G (passive) | Jun 30, 2025 |
| Venrock Healthcare Capital Partners EG, L.P. Joint filing with Venrock Healthcare Capital Partners III, L.P. (9.90%), VHCP Co-Investment Holdings III, LLC (9.90%) and 4 more | 1,391,196 | 9.90% | 13G (passive) | Jun 13, 2025 |
| Bvf Inc/Il Joint filing with Bvf Partners L P/Il (9.99%), Lampert Mark N (9.99%) and 3 more | 1,387,863 | 9.99% | 13G (passive) amendment | Jun 30, 2025 |
| Jiaqiang Li Joint filing with 1Globe Capital LLC (6.45%) | 896,712 | 6.45% | 13G (passive) | Aug 13, 2025 |
| Tang Capital Management, LLC Joint filing with Kevin Tang (5.04%) | 700,000 | 5.04% | 13G (passive) | Oct 2, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of CBIO | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 4,133,514 | 11.13% | $74.40M | – | 0.00% |
| Bvf Inc/Il | 2,748,763 | 7.40% | $49.48M | – | 1.27% |
| Fairmount Funds Management LLC | 2,747,866 | 7.40% | $49.46M | – | 3.27% |
| VR Adviser, LLC | 2,133,576 | 5.74% | $38.40M | – | 1.16% |
| Logos Global Management LP | 1,900,000 | 5.12% | $34.20M | +1,417,500 | 1.47% |
| Fcpm Iii Services B.V. | 1,677,852 | 4.52% | $30.20M | – | 4.02% |
| Balyasny Asset Management L.P. | 1,662,917 | 4.48% | $29.93M | +152,884 | 0.04% |
| Vestal Point Capital, LP | 1,630,000 | 4.39% | $29.34M | +130,000 | 0.69% |
| Opaleye Management Inc. | 1,319,351 | 3.55% | $23.75M | +6,736 | 2.15% |
| BlackRock, Inc. | 1,271,762 | 3.42% | $22.89M | +1,156,037 | 0.00% |
| Tang Capital Management LLC | 1,160,000 | 3.12% | $20.88M | – | 0.95% |
| Vanguard Capital Management LLC | 767,755 | 2.07% | $13.82M | −33,640 | 0.00% |
| Boxer Capital Management, LLC | 453,686 | 1.22% | $8.17M | – | 0.62% |
| Millennium Management LLC | 403,859 | 1.09% | $7.27M | +80,306 | 0.00% |
| Geode Capital Management, LLC | 384,576 | 1.04% | $6.92M | +280,355 | 0.00% |
| Jennison Associates LLC | 378,507 | 1.02% | $6.81M | +225,533 | 0.00% |
| NEXTBio Capital Management LP | 372,856 | 1.00% | $6.71M | – | 3.09% |
| Rtw Investments, LP | 372,856 | 1.00% | $6.71M | – | 0.06% |
| Remedium Capital Partners, LLC | 361,250 | 0.97% | $6.50M | – | 1.44% |
| State Street Corp | 315,587 | 0.85% | $5.68M | +276,520 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 82 | 30M | 79.7% | 31 / 17 | 15 / 12 | 5M | 2M |
| Q1 2026 | 63 | 26M | 69.9% | 17 / 18 | 8 / 11 | 4M | 2M |
| Q4 2025 | 58 | 24M | 64.9% | 23 / 17 | 9 / 6 | 14M | 1M |
| Q3 2025 | 41 | 11M | 30.5% | 15 / 7 | 9 / 4 | 2M | 2M |
| Q2 2025 | 30 | 11M | 28.9% | 30 / 0 | 0 / 0 | 11M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
14 funds held CBIO in Q2 2026, 92% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of CBIO | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 661,946 | 1.78% | $11.92M | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 83,801 | 0.23% | $1.51M | 0.00% | Jun 30, 2026 |
| Nuveen Small Cap Blend Index Fund | 28,660 | 0.08% | $414.71K | 0.01% | Jul 31, 2026 |
| Nuveen Equity Index Fund | 18,969 | 0.05% | $274.48K | 0.00% | Jul 31, 2026 |
| Avantis U.S. Small Cap Equity ETF | 15,612 | 0.04% | $322.39K | 0.01% | May 31, 2026 |
| Vanguard Balanced Index Fund | 11,212 | 0.03% | $201.82K | 0.00% | Jun 30, 2026 |
| Vanguard Institutional Total Stock Market Index Fund | 10,796 | 0.03% | $194.33K | 0.00% | Jun 30, 2026 |
| Global X Russell 2000 ETF | 10,277 | 0.03% | $148.71K | 0.01% | Jul 31, 2026 |
| Small Cap Index Fund | 10,253 | 0.03% | $184.55K | 0.01% | Jun 30, 2026 |
| Victory Extended Market Index Fund | 2,503 | 0.01% | $36.22K | 0.00% | Jul 31, 2026 |
| SmallCap Growth Fund I | 1,862 | 0.01% | $26.94K | 0.00% | Jul 31, 2026 |
| Ultra Small Cap Profund | 278 | 0.00% | $4.02K | 0.01% | Jul 31, 2026 |
| Knights of Columbus U.S. ALL CAP INDEX FUND | 120 | 0.00% | $1.74K | 0.00% | Jul 31, 2026 |
| Profund Vp Ultra Small Cap | 89 | 0.00% | $1.60K | 0.01% | Jun 30, 2026 |
| Profund Vp Small Cap | 58 | 0.00% | $1.04K | 0.01% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Joshua T. Brumm | Chief Executive Officer, Director | 271,765 | 0.73% | Sep 18, 2026 |
| Ellie Eunkyung Im | Chief Medical Officer | 21,446 | 0.06% | Sep 18, 2026 |
| Jan Pinkas | Chief Scientific Officer | 21,581 | 0.06% | Sep 18, 2026 |
| Jonathan McNeill | President and COO | 134,588 | 0.36% | Sep 18, 2026 |
| Richard William Scalzo | Chief Financial Officer | 19,730 | 0.05% | Sep 18, 2026 |
| Ryan Lynch | See Remarks | 13,631 | 0.04% | Sep 18, 2026 |
| Barbara Harlin Bispham | See Remarks | 18,710 | 0.05% | Sep 18, 2026 |
| Christopher Grant Doughty | Chief Business Officer | 62,194 | 0.17% | Dec 17, 2025 |
| Healthcare Fund II L.P. Fairmount | Director, 10% owner | 3,601,316 | 9.70% | Jul 20, 2026 |
| Tomas Kiselak | Director, 10% owner | – | – | Jul 20, 2026 |
| Funds Management LLC Fairmount | Director, 10% owner | – | – | Jul 20, 2026 |
| Peter Evan Harwin | Director, 10% owner | 2,747,866 | 7.40% | Jul 20, 2026 |
| David Charles Lubner | Director | – | – | Jun 3, 2026 |
| Susan Moran | Director | – | – | Jun 3, 2026 |
| Alexandra Balcom | Director | – | – | Jun 3, 2026 |
| Jonathan Violin | Director | 69,515 | 0.19% | Jun 3, 2026 |
| Ii Gp Llc Bvf | – | – | – | Jun 17, 2025 |
| Mark N. Lampert | 10% owner | – | – | Jun 17, 2025 |
| Value Fund Ii Lp Biotechnology | – | 2,955,440 | 7.96% | Jun 17, 2025 |
| I. Gp Llc Bvf | 10% owner | – | – | Jun 17, 2025 |
| Inc/Il Bvf | 10% owner | 4,980,812 | 13.41% | Jun 17, 2025 |
| Value Trading Fund OS LP Biotechnology | – | 1,644,624 | 4.43% | Jun 17, 2025 |
| Gp Holdings Llc Bvf | 10% owner | 707,116 | 1.90% | Jun 17, 2025 |
| Partners L. P/Il Bvf | 10% owner | – | – | Jun 17, 2025 |
| Value Fund L. P. Biotechnology | 10% owner | 2,265,606 | 6.10% | Jun 17, 2025 |
| Partners OS Ltd. BVF | – | – | – | Jun 17, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Joshua T. Brumm Chief Executive Officer, Director | Sep 18, 2026 | Sale(10b5-1 plan) | −7,837 | $16.71 | $130.96K | 271,765 |
| Jonathan McNeill President and COO | Sep 18, 2026 | Sale(10b5-1 plan) | −3,839 | $16.71 | $64.15K | 134,588 |
| Barbara Harlin Bispham See Remarks | Sep 16, 2026 | Sale(10b5-1 plan) | −620 | $17.90 | $11.10K | 18,710 |
| Joshua T. Brumm Chief Executive Officer, Director | Sep 16, 2026 | Sale(10b5-1 plan) | −1,610 | $17.90 | $28.82K | 279,602 |
| Ellie Eunkyung Im Chief Medical Officer | Sep 16, 2026 | Sale(10b5-1 plan) | −623 | $17.90 | $11.15K | 21,446 |
| Jan Pinkas Chief Scientific Officer | Sep 16, 2026 | Sale(10b5-1 plan) | −658 | $17.90 | $11.78K | 21,581 |
| Ryan Lynch See Remarks | Sep 16, 2026 | Sale(10b5-1 plan) | −240 | $17.90 | $4.30K | 13,631 |
| Richard William Scalzo Chief Financial Officer | Sep 16, 2026 | Sale(10b5-1 plan) | −568 | $17.90 | $10.17K | 19,730 |
| Jonathan McNeill President and COO | Sep 16, 2026 | Sale(10b5-1 plan) | −731 | $17.90 | $13.08K | 138,427 |
| Healthcare Fund II L.P. Fairmount Director, 10% owner | Jul 16, 2026 | Buy | +853,450 | $14.50 | $12.38M | 3,601,316 |
| Joshua T. Brumm Chief Executive Officer, Director | Jun 22, 2026 | Sale(10b5-1 plan) | −42,305 | $17.99 | $761.07K | 281,212 |
| Barbara Harlin Bispham See Remarks | Jun 22, 2026 | Sale(10b5-1 plan) | −1,218 | $17.99 | $21.91K | 19,330 |
| Ellie Eunkyung Im Chief Medical Officer | Jun 22, 2026 | Sale(10b5-1 plan) | −1,219 | $17.99 | $21.93K | 22,069 |
| Ryan Lynch See Remarks | Jun 22, 2026 | Sale(10b5-1 plan) | −465 | $17.99 | $8.37K | 13,871 |
| Richard William Scalzo Chief Financial Officer | Jun 22, 2026 | Sale(10b5-1 plan) | −1,112 | $17.99 | $20.00K | 20,298 |
| Jonathan McNeill President and COO | Jun 22, 2026 | Sale(10b5-1 plan) | −20,549 | $17.99 | $369.68K | 139,158 |
| Jan Pinkas Chief Scientific Officer | Jun 22, 2026 | Sale(10b5-1 plan) | −1,288 | $17.99 | $23.17K | 22,239 |
| Jonathan McNeill President and COO | Dec 15, 2025 | Award | +6,000 | – | – | 159,707 |
| Jonathan McNeill President and COO | Dec 15, 2025 | Award | +19,507 | – | – | 153,707 |
| Ryan Lynch See Remarks | Dec 15, 2025 | Award | +4,000 | – | – | 12,378 |
| Ryan Lynch See Remarks | Dec 15, 2025 | Award | +8,378 | – | – | 8,378 |
| Richard William Scalzo Chief Financial Officer | Dec 15, 2025 | Award | +5,000 | – | – | 19,422 |
| Richard William Scalzo Chief Financial Officer | Dec 15, 2025 | Award | +14,422 | – | – | 14,422 |
| Joshua T. Brumm Chief Executive Officer, Director | Dec 15, 2025 | Award | +10,000 | – | – | 323,517 |
| Joshua T. Brumm Chief Executive Officer, Director | Dec 15, 2025 | Award | +45,117 | – | – | 313,517 |
| Christopher Grant Doughty Chief Business Officer | Dec 15, 2025 | Award | +8,000 | – | – | 62,194 |
| Christopher Grant Doughty Chief Business Officer | Dec 15, 2025 | Award | +14,714 | – | – | 54,194 |
| Ellie Eunkyung Im Chief Medical Officer | Dec 15, 2025 | Award | +16,298 | – | – | 16,298 |
| Ellie Eunkyung Im Chief Medical Officer | Dec 15, 2025 | Award | +5,000 | – | – | 21,298 |
| Barbara Harlin Bispham See Remarks | Dec 15, 2025 | Award | +12,422 | – | – | 12,422 |
| Barbara Harlin Bispham See Remarks | Dec 15, 2025 | Award | +6,000 | – | – | 18,422 |
| Jan Pinkas Chief Scientific Officer | Dec 15, 2025 | Award | +17,507 | – | – | 17,507 |
| Jan Pinkas Chief Scientific Officer | Dec 15, 2025 | Award | +5,000 | – | – | 22,507 |
| Peter Evan Harwin Director, 10% owner | Dec 4, 2025 | Buy | +1,360,000 | $13.41 | $18.24M | 2,747,866 |
| Gp Holdings Llc Bvf 10% owner | Jun 13, 2025 | Other | +657,308 | – | – | 707,116 |
| Gp Holdings Llc Bvf 10% owner | Jun 13, 2025 | Other | +556,617 | – | – | 593,740 |
| Gp Holdings Llc Bvf 10% owner | Jun 13, 2025 | Other | +56,079 | – | – | 62,383 |
| Siren, L.L.C. 10% owner | Aug 8, 2024 | Sale | −260,873 | $0.19 | $49.57K | 6,317,565 |
| Siren, L.L.C. 10% owner | Aug 7, 2024 | Sale | −61,488 | $0.18 | $11.07K | 6,578,438 |
| Invus Public Equities Advisors, LLC 10% owner | Aug 6, 2024 | Sale | −55,732 | $0.18 | $10.03K | 6,639,926 |
| Invus Public Equities Advisors, LLC 10% owner | Aug 5, 2024 | Sale | −164,523 | $0.19 | $31.26K | 6,695,658 |
| Siren, L.L.C. 10% owner | Aug 2, 2024 | Sale | −286,200 | $0.20 | $57.24K | 6,860,181 |
| Siren, L.L.C. 10% owner | Aug 1, 2024 | Sale | −63,564 | $0.22 | $13.98K | 7,146,381 |
| Siren, L.L.C. 10% owner | Jul 30, 2024 | Sale | −756,835 | $0.22 | $166.50K | 7,209,945 |
| Siren, L.L.C. 10% owner | Jul 29, 2024 | Sale | −363,949 | $0.24 | $87.35K | 7,966,780 |
| Siren, L.L.C. 10% owner | Jul 26, 2024 | Sale | −258,335 | $0.24 | $62.00K | 8,330,729 |
| Edwin Rock Chief Medical Officer | Jun 21, 2024 | Buy | +115,000 | $0.27 | $31.05K | 680,403 |
| Edwin Rock Chief Medical Officer | Jun 20, 2024 | Buy | +190,000 | $0.25 | $47.50K | 565,403 |
| Brian M. Hahn SVP Finance, CFO | Jun 18, 2024 | Buy | +17,500 | $0.25 | $4.38K | 70,643 |
| Mark Alan Goldberg Director | Mar 29, 2024 | Award | +4,584 | $3.00 | $13.75K | 24,828 |
| Daniel M. Junius Director | Mar 29, 2024 | Award | +5,209 | $3.00 | $15.63K | 98,459 |
| Rachel K. King Director | Mar 29, 2024 | Award | +3,334 | $3.00 | $10.00K | 515,194 |
| Mark Alan Goldberg Director | Dec 29, 2023 | Award | +5,827 | $2.36 | $13.75K | 20,244 |
| Patricia S. Andrews Director | Dec 29, 2023 | Award | +5,191 | $2.36 | $12.25K | 58,608 |
| Rachel K. King Director | Dec 29, 2023 | Award | +4,238 | $2.36 | $10.00K | 511,860 |
| Rachel K. King Director | Sep 30, 2023 | Award | +6,667 | $1.50 | $10.00K | 507,622 |
| Patricia S. Andrews Director | Sep 30, 2023 | Award | +8,167 | $1.50 | $12.25K | 53,417 |
| Mark Alan Goldberg Director | Sep 30, 2023 | Award | +9,167 | $1.50 | $13.75K | 14,417 |
| Edwin Rock Chief Medical Officer | Sep 22, 2023 | Buy | +30,403 | $1.38 | $41.96K | 375,403 |
| Edwin Rock Chief Medical Officer | Sep 21, 2023 | Buy | +35,000 | $1.38 | $48.30K | 345,000 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
18.26%
4M shares short
Days to cover
16.3
At 0M shares a day
Change since last report
-5.8%
From 4M shares
Short volume, 20 days
64.6%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Crescent Biopharma's stock actually held short. Settlement fails (shares not delivered on time) peaked at 2,299 shares on Sep 24, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Joshua T. Brumm Officer, Director | Sep 17, 2026 | 9,013 | $154.84K | Sep 18, 2026 | Restricted Stock Unit Vesting |
| Jonathan McNeill Officer | Sep 17, 2026 | 4,415 | $75.85K | Sep 18, 2026 | Restricted Stock Unit Vesting |
| Jonathan McNeill Officer | Sep 16, 2026 | 804 | $15.12K | Sep 16, 2026 | Restricted Stock Unit Vesting |
| Joshua T. Brumm Officer, Director | Sep 16, 2026 | 1,771 | $33.29K | Sep 16, 2026 | Restricted Stock Unit Vesting |
| Brian M. Hahn Officer | May 17, 2023 | 4,313 | $8.45K | May 17, 2023 | Stock Plan Activity |
See a number that looks wrong?